Registers – Systems controlled by data bearing records – Credit or identification card systems
Reexamination Certificate
2005-06-07
2010-02-23
Labaze, Edwyn (Department: 2887)
Registers
Systems controlled by data bearing records
Credit or identification card systems
C235S375000, C235S487000, C705S044000, C705S075000
Reexamination Certificate
active
07665658
ABSTRACT:
A transaction aggregation method that includes the steps of receiving user data and a current transaction amount associated with a current transaction, and retrieving a reliability score for the user with the user data, and calculating an aggregation threshold based on the reliability score. The method also includes updating an aggregated transaction amount by adding the current transaction amount to a previously aggregated transaction amount from previous transactions, and comparing the updated aggregated amount with the aggregation threshold, where the current transaction is aggregated with the previous transactions when the updated aggregated amount is less than the aggregation threshold.
REFERENCES:
patent: 6094643 (2000-07-01), Anderson et al.
patent: 7225977 (2007-06-01), Davis
patent: 7263506 (2007-08-01), Lee et al.
patent: 2002/0049760 (2002-04-01), Scott et al.
patent: 2002/0103998 (2002-08-01), DeBruine
patent: 2002/0138291 (2002-09-01), Vaidyanathan et al.
patent: 2002/0138362 (2002-09-01), Kitze et al.
patent: 2002/0138440 (2002-09-01), Vaidyanathan et al.
patent: 2002/0138552 (2002-09-01), DeBruine et al.
patent: 2002/0138576 (2002-09-01), Schleicher et al.
patent: 2002/0138744 (2002-09-01), Schleicher et al.
patent: 2002/0194108 (2002-12-01), Kitze
patent: 2002/0194119 (2002-12-01), Wright et al.
patent: 2003/0061287 (2003-03-01), Yu et al.
patent: 2003/0126036 (2003-07-01), Mascavage et al.
patent: 2004/0153389 (2004-08-01), Lortscher, Jr.
patent: 2004/0199475 (2004-10-01), Rivest et al.
patent: 2004/0243832 (2004-12-01), Wilf et al.
patent: 2005/0044224 (2005-02-01), Jun et al.
patent: 2005/0097320 (2005-05-01), Golan et al.
patent: 2006/0202012 (2006-09-01), Grano et al.
patent: 2007/0106517 (2007-05-01), Cluff et al.
patent: 3930266 (1991-03-01), None
patent: 1 122 257 (2005-10-01), None
patent: WO 95/13279 (1995-03-01), None
patent: WO 95/15327 (1995-06-01), None
patent: WO 96/07656 (1996-03-01), None
patent: WO 97/11945 (1997-04-01), None
patent: WO 98/06725 (1998-02-01), None
patent: WO 00/38680 (2000-07-01), None
patent: WO 00/39125 (2000-07-01), None
patent: WO 00/55143 (2000-09-01), None
patent: WO 00/66558 (2000-11-01), None
patent: WO 00/66559 (2000-11-01), None
patent: WO 01/44243 (2001-06-01), None
patent: WO 01/90106 (2001-11-01), None
patent: WO 02/07523 (2002-01-01), None
patent: WO 02/060902 (2002-08-01), None
patent: WO 03/097646 (2003-11-01), None
patent: WO 2004/056773 (2004-07-01), None
Abou-Gharbia, M.,Synthesis and Structure-Activity Relationship of Substituted Tetrahydro- and Hexahydro-1,2-benziosothiazol-3-one, 1,1-Dioxides and Thiadiazinoes: Potential Anxiolytic Agents, J. Med. Chem., 1989, pp. 1024-1033, vol. 32.
Agawal, L.,Chemokine receptors: emerging opportunities for new anti-HIV therapies, Expert Opin. Ther. Targets, 2001, pp. 303-326, vol. 5(3).
Baba, M.,A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity, Proc. Nat. Acad. Sci. USA, 1999, pp. 5698-5703, vol. 96.
De Clerq, E.,Emerging anti-HIV Drugs, Exp. Opin. Emerg. Drugs, 2005, pp. 241-274, vol. 10.
Dorr, P.,Abstr. of the 11thConf. on Retroviruses and Opportunistic Infect., San Francisco, CA, USA, Feb. 10-14, 2003, Abstract, 12.
Dooseop, K..,Discovery of Human CCR5 Antagonists Containing Hydantoins for the Treatment of HIV-1 Infection, Bioorg. Med. Chem. Lett., 2001, pp. 3099-3102, vol. 11.
Dorr, P.,Maraviroc(UK-427, 857),a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity, Antimicrob. Agents Chemother., 2005, pp. 4721-4732, vol. 49(11).
Finke, P.,Antagonists of the Human CCR5 Receptor as Anti-HIV-1 Agents. Part 4: Synthesis and Structure-Activity Relationships for 1-[N-(Methyl)-N-(phenylsulfony)amino]-2-(phenyl)-4-(4-N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes, Bioorg. Med. Chem. Lett., 2001, pp. 2475-2479, vol. 11.
Finke, P.,Antagonists of the Human CCR5 Receptor as anti-HIV-1 agents, Part 2: Structure-Activity Relationships for Substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes, Biorg. Med. Chem. Lett., 2001, pp. 265-270, vol. 11.
Finke, P.Antagonists of the Human CCR5 Receptor as Anti-HIV-1 Agents. Part 3: a Proposed Pharmacophore Model for 1-[N-(Methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl[butanes, Bioorg. Med. Chem. Lett., 2001, pp. 2469-2473, vol. 11.
Hale, J.,1,3,4-Trisubstituted Pyrrolidine CCR5 Receptor Antagonists. Part 2: Lead Optimization Affording Selective, Orally Bioavailable Compounds with Potent Anti-HIV activity, Bioorg. Med. Chem. Lett., 2001, pp. 2741-2745, vol. 11.
Kazmierski, W.,Recent Progress in Discovery of Small-Molecule CCR5 Chemokine Receptor Ligands as HIV-1 Inhibitors, Biorg. Med. Chem., 2003, pp. 2663-2676, vol. 11.
Macartney, M., 43rdlntersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, USA, Sep. 14-17, 2003, Abstract, H-875.
Maeda, K.,Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCRD, J. Biol. Chem., 2001, pp. 35194-35200, vol. 276(37).
Maeda, K.,Spriodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro, J. Virol., 2004, pp. 8654-8662, vol. 78(16).
Maeda, K.,The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection, Curr. Opin. Pharmacol., 2004, pp. 447-452, vol. 4.
Obst, U.,Synthesis of Novel Nonpeptidic Thrombin Inhibitors, Helv. Chim. Acta., 2000, pp. 855-909, vol. 83.
Palani, A.,Discovery of 4-[(Z)-(4-Bromophenyl)-(ethoxylimino)methyl]-1′-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4′-methyl-1,4′-bipiperidine N-Oxide(SCH 351125):An Orally Bioavailable Human CCR5 Antagonist for the Treatment of HIV Infection, J. Med Chem., 2001, pp. 3339-3342, vol. 44(21).
Shiraishi, M.Discovery of Novel, Potent, and Selective Small-Molecule CCR5 Antagonists as Anti-HIV-1 Agents: Synthesis and Biological Evaluation of Anilide Derivatives with a Quaternary Ammonium Moiety, J. Med. Chem., 2000, pp. 2049-2063, vol. 43(10).
Strizki, J.,SCH-C(SCH 351125),an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo, Proc. Nat. Acad. Sci. USA, 2001, pp. 12718-12723, vol. 98.
Tagat, J.,Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors, II. Discovery of 1-[2,4-Dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluromethyl)phenyl]ethyl]-1-piperazinyl]-piperidine N1-Oxide(Sch350634),an Orally Bioavailable, Potent CCR5 Antagonist, J. Med. Chem., 2001, pp. 3343-3346, vol. 44(21).
Watson, C.,The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor, Mol. Pharm., 2005, pp. 1268-1282, vol. 67(4).
Wood, A.,The Discovery of the CCR5 Receptor Antagonist, UK-427,857, A New Agent for the Treatment of HIV Infection and AIDS, Prog. Med. Chem., 2005, pp. 239-271, vol. 43.
First Data Corporation
Labaze Edwyn
Townsend and Townsend / and Crew LLP
LandOfFree
Dynamic aggregation of payment transactions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dynamic aggregation of payment transactions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dynamic aggregation of payment transactions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4165196